Cardiovascular Conference Series: Neuroendovascular Management of Emergent Large Vessel Occlusions
Acute ischemic stroke (AIS) is the fifth leading cause of death, and remains the leading cause of disability in the U.S. There are an estimated 680 000 new strokes per year in the nation, with a mortality rate of 53%–94%, and an even greater morbidity. It is estimated that 3–22% of these patients are candidates for endovascular therapy. In addition to baseline stroke severity, emergent large vessel occlusion (ELVO) has been shown to be an independent predictor of poor outcome at six months. While intravenous recombinant tissue plasminogen activator (IV r-tPA) has proven efficacious predominantly for small cerebral vessel occlusions, endovascular therapies, including stent retriever based, and aspiration-based mechanical thrombectomy techniques, and intra-arterial administration of thrombolytic agents have been shown to achieve higher rates of recanalization in patients with ELVO. Please join Dr. Guilherme Dabus as he presents on the neuroendovascular management of emergent large vessel occlusions.
|Live- Baptist Hospital 5MCVI|
|Webcast - Webcast Link once course has started|
Cardiologists, Interventional Cardiologists, Interventional Radiologists, Neurologists, Internists, Emergency Medicine Physicians, Family Physicians, Hospitalists, Nurses, Pharmacists, Radiology Technicians, Respiratory Therapists and all other interested healthcare providers.
- Effectively identify patients who would benefit from endovascular treatment of acute stroke due to large vessel occlusions, and identify appropriate treatment.
Guilherme Dabus, M.D., FAHA
Director, Neuro-Interventional Surgery Fellowship Program
Miami Cardiac & Vascular Institute
Baptist Neuroscience Center
Florida International University Herbert Wertheim College of Medicine
Dr. Guilherme Dabus is a consultant for Microvention, Medtronic, Penumbra, Codman Cerenovus and InNueroCo. He is a member of the Speakers’ Bureau for Microvention, Medtronic, and Penumbra. He is a shareholder for Surpass/Stryker, Medina/Medtronic, InNeuroCo, Three Rivers Medical, eLum and Cleerly. He has indicated that he will not include off-label or unapproved product usage in his presentation or discussion.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-103402, by the Florida Boards of Medicine and Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 1 credit hour for Nurses and Nurse Practitioners. Baptist Health South Florida CE Broker Provider #50-182.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Florida Board of Nursing
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Pharmacy
- 1.00 Florida Bureau of Radiation Control
- 1.00 Florida Board of Respiratory Therapy
- 1.00 General certificate of attendance
Technical Support: If you are experiencing technical difficulties or have received an error message, please send an email to CME@BaptistHealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.